There were significant differences in age; educational level; BMI; DBP on admission; heart rate; presence of co-morbidities, including diabetes mellitus and atrial fibrillation; NIHSS score; blood parameters, including total cholesterol, TG, HDL cholesterol, LDL cholesterol, FPG, TyG, alanine aminotransferase, eGFR, uric acid, leukocyte count, INR; Pharmacotherapy information, including antidiabetic drug therapy and lipid-lowering drug therapy among different TyG-BMI levels (P < 0.05). This evidence concerns the gene GPT and atrial fibrillation.